Gleevec News and Research

RSS

Gleevec is a drug used to treat different types of leukemia and other cancers of the blood, gastrointestinal stromal tumors, skin tumors called dermatofibrosarcoma protuberans, and a rare condition called systemic mastocytosis. It is also being studied in the treatment of other types of cancer. Gleevec blocks the protein made by the bcr/abl oncogene. It is a type of tyrosine kinase inhibitor. Also called imatinib mesylate and STI571.

FDA grants accelerated approval for Sprycel (dasatinib)

FDA grants accelerated approval for Sprycel (dasatinib), a new oral treatment for patients with chronic myeloid leukemia (CML),

29 Jun 2006

New leukemia drug gives renewed hope to those battling drug resistance to the disease

New research offers hope for victims of chronic myeloid leukemia (CML) battling drug resistance to the disease.

18 Jun 2006

Dasatinib offers new options for leukemia patients

Dasatinib, an experimental drug under development by Bristol-Myers Squibb, reverses the signs and symptoms of patients whose chronic myeloid leukemia has failed to respond to Gleevec, which is considered the standard of treatment for the disorder.

14 Jun 2006

Gleevec strangles drug-resistant, metastatic prostate cancer

A medication used to treat other types of cancer strangles drug-resistant, metastatic prostate cancer by cutting off its blood supply, researchers from The University of Texas M. D. Anderson Cancer Center report in the June 7 issue of the Journal of the National Cancer Institute.

7 Jun 2006

Long-term benefits of imatinib for patients newly diagnosed with chronic myelogenous leukemia

The overall survival of most people with chronic myelogenous leukemia (CML) treated with imatinib (Gleevec, STI-571) is extremely high and the relapse rate is quite low, according to new data from a study out of the Oregon Health & Science University Cancer Institute.

6 Jun 2006

Study confirms Gleevec's long-term benefits in treating advanced gastrointestinal stromal tumors

People with advanced gastrointestinal stromal tumors (GIST) who take Gleevec (imatinib) for prolonged periods continue to benefit from the drug, according to a five-year study by Oregon Health & Science University Cancer Institute researchers.

6 Jun 2006

New compound shows unique potency against cancer cell proliferation

By determining how a class of compounds blocks signaling in cells, University of California, San Francisco (UCSF) scientists have identified what is perhaps the most potent drug candidate yet against a highly lethal kind of brain tumor.

16 May 2006

Cancer treatment interferes with bone development

According to researchers in the U.S. the cancer drug Gleevec (imatinib), which has dramatically improved survival prospects for some cancer patients, can interfere with bone development.

11 May 2006

Promising chemo, therapeutic viruses, cutting-edge surgery debut at M. D. Anderson Cancer Center

Brain tumor specialists at The University of Texas M. D. Anderson Cancer Center are poised on the brink of a new era.

10 May 2006

Finding indicate why some kinds of Leukemia are more aggressive than others

New clues to why some kinds of leukemia are more aggressive and deadly than others are coming from research examining the types of genetic damage that allow some blood cells to grow out of control, scientists report.

28 Apr 2006

Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia

23 Apr 2006

Dasatinib provides significant benefit in chronic myeloid leukemia patients resistant to Gleevec

A study led by researchers from the Howard Hughes Medical Institute has found that dasatinib provides significant benefit in chronic myeloid leukemia (CML) patients resistant to Gleevec. (imatinib), according to a study presented during the 97th Annual Meeting of the American Association for Cancer Research.

11 Apr 2006

New way to study proteins in live cells

For the first time, Johns Hopkins researchers were able to easily jumpstart the activity of a well-known cancer protein in live cells with a small molecule, a strategy that pinpointed key players in the cancer process and can be used to determine new therapeutic targets.

9 Mar 2006

Interferon-producing killer dendritic cell speeds up immune reactions and fights cancer

A mouse immune cell that plays dual roles as both assassin and messenger, normally the job of two separate cells, has been discovered by an international team of researchers from the United States and France.

7 Mar 2006

Genzyme launches test to monitor Gleevec resistance

Genzyme Corporation has announced the availability of an important new test to monitor drug resistance in chronic myeloid leukemia (CML) patients who are treated with Gleevec (imatinib mesylate).

13 Feb 2006

Mutated oncogene triggers aggressive breast cancer

Researchers at Dana-Farber Cancer Institute have identified a molecular interaction that triggers a particularly aggressive form of breast cancer, and suggest that attacking this target with selective drugs might improve treatment.

18 Jan 2006

Imatinib mesylate (Gleevec) may not be effective at treating kidney cancer

Mayo Clinic Cancer Center investigators report that imatinib mesylate (GleevecTM), the drug used to treat patients with gastrointestinal stromal cancers (GISTs), is not likely to be effective for patients with high grade renal cell carcinoma -- the most aggressive kidney cancer.

22 Dec 2005